Literature DB >> 3125292

Studies of cholecystokinin-stimulated biliary secretions reveal a high molecular weight copper-binding substance in normal subjects that is absent in patients with Wilson's disease.

V Iyengar1, G J Brewer, R D Dick, O Y Chung.   

Abstract

Copper is unique among cations in that its balance is regulated by the liver. The liver regulates copper balance by excretion of copper (we call it regulatory copper) in the bile destined for loss in the stool. However, most copper secreted into the gastrointestinal tract, for example, that in saliva and gastric juice, is reabsorbed. The biochemical mechanism by which the normal liver "packages" regulatory copper to prevent its reabsorption is not understood. Whatever the mechanism, it appears to have failed in Wilson's disease, because patients with Wilson's disease do not excrete adequate amounts of regulatory copper in their bile to prevent copper accumulation. In the present work, we have studied cholecystokinin-stimulated biliary secretions obtained by intestinal intubation of five normal subjects and five patients with Wilson's disease. Studies of these secretions reveal: (1) that normal but not Wilson's disease biliary samples had a copper-containing peak in the void volume from Sephadex G-75 columns; (2) that the amount of copper in this peak extrapolated to 24 hours of secretion was appropriate to maintain normal copper balance; (3) that the amount of copper in this peak increased with dietary copper supplementation of normal subjects; (4) that normal but not Wilson's disease biliary samples cross-reacted with each of two ceruloplasmin antibodies; and (5) that the high molecular weight Sephadex G-75 fraction from normal but not from Wilson's disease biliary samples cross-reacted with ceruloplasmin antibody. We postulate that the high molecular weight copper-containing substance observed with Sephadex chromatography in normal biliary samples but absent in Wilson's disease samples is the copper-packaging mechanism for copper balance regulation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3125292

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  8 in total

1.  Orthotopic liver transplantation in liver-based metabolic disorders.

Authors:  A P Mowat
Journal:  Eur J Pediatr       Date:  1992       Impact factor: 3.183

2.  Two forms of Wilson disease protein produced by alternative splicing are localized in distinct cellular compartments.

Authors:  X L Yang; N Miura; Y Kawarada; K Terada; K Petrukhin; T Gilliam; T Sugiyama
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

3.  Comparative study of biliary trace elements and clinical phenotypes in Wilson's disease.

Authors:  M S Ren; Y X Fan; R M Yang; Y Z Han; G J Wu; Y R Xin; L Yu
Journal:  World J Gastroenterol       Date:  1997-12-15       Impact factor: 5.742

4.  Caeruloplasmin isoforms in Wilson's disease in neonates.

Authors:  G F Chowrimootoo; H Scowcroft; C A Seymour
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-11       Impact factor: 5.747

Review 5.  Aetiology and pathophysiology of chronic liver disorders.

Authors:  J Schölmerich; A Holstege
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 6.  Copper and liver disease.

Authors:  D M Danks
Journal:  Eur J Pediatr       Date:  1991-01       Impact factor: 3.183

7.  'Free' copper in serum of Alzheimer's disease patients correlates with markers of liver function.

Authors:  R Squitti; M Ventriglia; G Barbati; E Cassetta; F Ferreri; G Dal Forno; S Ramires; F Zappasodi; P M Rossini
Journal:  J Neural Transm (Vienna)       Date:  2007-07-04       Impact factor: 3.575

Review 8.  Copper Homeostasis in Mammals, with Emphasis on Secretion and Excretion. A Review.

Authors:  Maria C Linder
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.